Introduction
Ferran Navarro and Jesús Rodríguez-Baño Enferm Infecc Microbiol Clin. 2007;25 Supl 2:1 Conflict of interest: Ferran Navarro declares he has no conflict of interest. Jesús Rodríguez-Baño declares he has been a scientific advisor and speaker for MSD, Wyeth, Roche and Pfizer.
Evolution and current situation of ESBL
Rafael Cantón, Aránzazu Valverde, Ángela Novais, Fernando Baquero and Teresa Coque Enferm Infecc Microbiol Clin. 2007;25 Supl 2:2-10 Conflict of interest: the authors declare they have no conflict of interest.
The genetic environment of ESBL: implications in transmission
Ferran Navarro and Elisenda Miró Enferm Infecc Microbiol Clin. 2007;25 Supl 2:11-7 Conflict of interest: the authors declare they have no conflict of interest.
Epidemiology and control of nosocomial ESBL-producing microorganisms
Carmen Peña and Miquel Pujol Enferm Infecc Microbiol Clin. 2007;25 Supl 2:18-22 Conflict of interest: the authors declare they have no conflict of interest.
Epidemiology of ESBL in the community. An increasing problem
Lorena López-Cerero and Alvaro Pascual Enferm Infecc Microbiol Clin. 2007;25 Supl 2:23-8 Conflict of interest: Lorena López Cerero declares she has no conflict of interest. Álvaro Pascual declares he has been a speaker in a symposium organized by AstraZeneca.
ESBL in animals and their importance in transmission to humans
Carmen Torres and Myriam Zarazaga Enferm Infecc Microbiol Clin. 2007;25 Supl 2:29-37 Conflict of interest: the authors declare they have no conflict of interest.
Association of ESBL with other resistance mechanisms
Luis Martínez-Martínez Enferm Infecc Microbiol Clin. 2007;25 Supl 2:38-47 Conflict of interest: the author declares he has been a consultant for Wyeth, participated in conferences sponsored by Chiron, Wyeth and GSK, and has received research funds from Chiron, Wyeth, GSK, MSD and Pfizer.
Importance of ESBL in the prognosis and cost of infections
José Miguel Cisneros and Elisa Cordero Enferm Infecc Microbiol Clin. 2007;25 Supl 2:48-53 Conflict of interest: the authors declare they have no conflict of interest.
Impact of ESBL on empirical therapy and antibiotic policies
Jesús Rodríguez-Baño and María Dolores Navarro Enferm Infecc Microbiol Clin. 2007;25 Supl 2:54-9 Conflict of interest: Jesús Rodríguez-Baño declares he has been a scientific advisor and speaker for MSD, Wyeth, Roche and Pfizer. María Dolores Navarro declares she has no conflict of interest.
Treatment of ESBL producers
David L. Paterson Enferm Infecc Microbiol Clin. 2007;25 Supl 2:60-3 Conflict of interest: the author has grants from the Centers for Disease Control and Prevention, National Institutes of Health and AstraZeneca Pharmaceuticals. He has been a consultant to the following companies: Acureon, Merck, Protez, AstraZeneca, Elan, Johnson and Johnson, and Rib-X.
